NBIX vs SPG · P/E 45, rev $1.77B vs rev $3.55B
Neurocrine Biosciences Inc (NBIX) versus SPG (SPG) — a side-by-side from cached financials, not a winner call.
Neurocrine Biosciences Inc (NBIX) is a drug manufacturers - specialty & generic company listed on US.
SPG (SPG) common stock.
Latest reported NBIX revenue for 2026-06-30 was $1.77B. Net income was $342.3M. NBIX currently screens at market cap $13.21B and trailing P/E 45.2.
Latest reported SPG revenue for 2026-06-30 was $3.55B. Net income was $1.14B. SPG currently screens at market cap $0.
NBIX currently screens at market cap $13.21B and trailing P/E 45.2. SPG currently screens at market cap $0.
Not investment advice. Open the NBIX and SPG stock pages for the full models.
Not investment advice.